Reconsidering Ibogaine for the treatment of severe mental illness and substance use disorders

Ibogaine, a psychoactive compound from the Tabernanthe iboga plant, shows promise for easing withdrawal symptoms, reducing cravings, and improving psychiatric symptoms in people with severe mental illness and co-occurring substance use disorders. However, safety concerns, especially heart function risks like QT interval prolongation and life-threatening arrhythmias, limit its clinical use. Key research priorities include large-scale randomized controlled trials with personalized dosing, safer synthetic alternatives, studies of its neurobiological effects, and tracking long-term outcomes to safely harness its potential.

Study at a glance

Abstract

Severe mental illness (SMI) and co-occurring substance use disorders (SUDs) continue to pose a major global health challenge, contributing to high rates of mortality, disability, and economic strain. Ibogaine, a naturally occurring psychoactive compound derived from the Tabernanthe iboga plant, has shown promise in easing withdrawal symptoms, reducing cravings, and improving psychiatric symptoms linked to addiction. While early observational studies and a growing number of clinical trials are encouraging, concerns about safety—particularly its impact on heart function, such as QT interval prolongation and the risk of life-threatening arrhythmias—have limited its broader clinical use. Moving forward, key research priorities include conducting large-scale randomized controlled trials with personalized dosing strategies, developing safer synthetic alternatives, investigating the drug’s underlying neurobiological effects, and tracking long-term outcomes. Closing these gaps is crucial to fully understand and safely harness ibogaine’s potential for treating SMI and SUDs.